Press Releases May 1, 2026 06:30 AM

nVent Electric plc First Quarter 2026 Financial Results Available on Company’s Website

nVent Electric plc announces Q1 2026 financial results and schedules earnings call

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
NVT

nVent Electric plc, a global leader in electrical connection and protection solutions, has released its first quarter 2026 financial results via its investor relations website and SEC filing. The company has also announced a conference call to discuss the earnings with analysts and investors.

nVent Electric plc First Quarter 2026 Financial Results Available on Company’s Website
NVT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • nVent reported Q1 2026 financial results with details available on their investor website and SEC filings.
  • A conference call and webcast are scheduled to discuss the earnings results with analysts and investors.
  • nVent is a global provider of electrical connection and protection products with a portfolio of well-known brands and a history exceeding 100 years.

LONDON, May 01, 2026 (GLOBE NEWSWIRE) -- nVent Electric plc (NYSE:NVT) (“nVent”), a global leader in electrical connection and protection solutions, reported first quarter 2026 financial results today through an earnings release posted on the company’s Investor Relations website at http://investors.nvent.com. The earnings release will be furnished with the Securities and Exchange Commission on a Form 8-K and is available here. The company will also hold a conference call with analysts and investors at 9:00 a.m. ET.

Conference Call and Webcast Details

The call can be accessed via webcast at http://investors.nvent.com or by dialing 1-833-630-1071 or 1-412-317-1832. Once available, a replay of the conference call will be accessible through May 15, 2026, by dialing 1-855-669-9658 or 1-412-317-0088, along with the access code 3392967.

About nVent
nVent is a leading global provider of electrical connection and protection solutions. We believe our inventive electrical solutions enable safer systems and ensure a more secure world. We design, manufacture, market, install and service high performance products and solutions that connect and protect some of the world's most sensitive equipment, buildings and critical processes. We offer a comprehensive range of systems protection and electrical connections solutions across industry-leading brands that are recognized globally for quality, reliability and innovation. Our principal office is in London and our management office in the United States is in Minneapolis. Our robust portfolio of leading electrical product brands dates back more than 100 years and includes nVent CADDY, ERICO, HOFFMAN, ILSCO, SCHROFF and TRACHTE. Learn more at www.nvent.com.

nVent, CADDY, ERICO, HOFFMAN, ILSCO, SCHROFF and TRACHTE are trademarks owned or licensed by nVent Services GmbH or its affiliates.

Investor Contact
Tony Riter
Vice President, Investor Relations
nVent
763.204.7750
tony.riter@nVent.com

Media Contact
Kevin H. King
Vice President, Global Communications
nVent
763.291.0526
kevin.king@nvent.com


Risks

  • Financial results may reveal revenue or profit below market expectations impacting stock negatively.
  • Global supply chain or production challenges could affect future financial performance.
  • Market competition in electrical connection and protection solutions sectors could impact growth and profitability.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026